We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-11.79%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$29.8M
Cap. Flow
+$9.22M
Cap. Flow %
4.06%
Top 10 Hldgs %
39.83%
Holding
81
New
31
Increased
12
Reduced
7
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.7M
2
AZN icon
AstraZeneca
AZN
+$8.94M
3
EHC icon
Encompass Health
EHC
+$8.33M
4
CTLT
CATALENT, INC.
CTLT
+$8.19M
5
DHR icon
Danaher
DHR
+$7.6M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$14.5M
2
DXCM icon
DexCom
DXCM
+$13.1M
3
AMED
Amedisys
AMED
+$10.8M
4
SNY icon
Sanofi
SNY
+$9.54M
5
VAR
Varian Medical Systems, Inc.
VAR
+$8.52M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Energy 3.09%
3 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WBA
26
DELISTED
Walgreens Boots Alliance
WBA
$3.66M 1.61%
+80,000
New +$4.06M
ABT icon
27
Abbott
ABT
$190B
$3.55M 1.56%
+45,000
New +$3.75M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$3.51M 1.55%
60,000
+40,000
+200% +$2.57M
ISRG icon
29
Intuitive Surgical
ISRG
$142B
$3.47M 1.53%
+21,000
New +$3.85M
DRNA
30
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.4M 1.5%
185,000
-15,000
-8% -$292K
RVTY icon
31
Revvity
RVTY
$12.9B
$3.39M 1.49%
+45,000
New +$3.99M
MCK icon
32
McKesson
MCK
$105B
$3.38M 1.49%
+25,000
New +$3.66M
NVO
33
Novo Nordisk
NVO
$207B
$3.31M 1.46%
110,000
+30,000
+38% +$893K
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.08M 1.35%
40,000
+25,000
+167% +$2.24M
EXEL icon
35
Exelixis
EXEL
$12.7B
$2.58M 1.14%
+150,000
New +$2.74M
UNH icon
36
UnitedHealth
UNH
$365B
$2.49M 1.1%
+10,000
New +$2.75M
TXG icon
37
10x Genomics
TXG
$7.62B
$2.49M 1.1%
40,000
+15,000
+60% +$1.17M
ALKS icon
38
Alkermes
ALKS
$8.26B
$2.16M 0.95%
+150,000
New +$2.68M
FATE icon
39
Fate Therapeutics
FATE
$319M
$2.11M 0.93%
+95,000
New +$2.4M
KPTI icon
40
Karyopharm Therapeutics
KPTI
$47.6M
$1.92M 0.85%
6,667
-16,333
-71% -$4.51M
EXEL icon
41
CALL
Exelixis
EXEL
$12.7B
$1.72M 0.76%
+100,000
New +$1.83M
BMY.RT
42
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.71M 0.75%
450,000
-100,000
-18% -$329K
ARVN icon
43
Arvinas
ARVN
$588M
$1.61M 0.71%
+40,000
New +$1.87M
DNLI icon
44
Denali Therapeutics
DNLI
$3.95B
$1.58M 0.69%
+90,000
New +$1.88M
HUM icon
45
Humana
HUM
$44.8B
$1.57M 0.69%
5,000
-18,000
-78% -$6.07M
AKBA icon
46
Akebia Therapeutics
AKBA
$240M
$1.52M 0.67%
+200,000
New +$1.56M
NERV icon
47
Minerva Neurosciences
NERV
$206M
$1.5M 0.66%
31,250
+8,750
+39% +$528K
AKRO
48
DELISTED
Akero Therapeutics
AKRO
$1.27M 0.56%
+60,000
New +$1.29M
HALO icon
49
Halozyme
HALO
$11.6B
$900K 0.4%
+50,000
New +$949K
AMRN
50
CALL
Amarin Corp
AMRN
$296M
$800K 0.35%
+10,000
New +$3.32M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Integral Health Asset Management held 81 positions worth $227M, down 12% from $257M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Integral Health Asset Management deployed $9.22M of net new capital in Q1 2020, opening 31 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 136,240 shares worth $10M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Energy and Consumer Discretionary.

On the sell side, the largest reduction was Humana, an estimated $6.07M trimmed.

  • Integral Health Asset Management's largest Q1 2020 buy was Merck: 136,240 shares worth $10M.
  • Integral Health Asset Management added most to ChemoCentryx, Inc. in Q1 2020, an estimated $5.94M increase.
  • Integral Health Asset Management's biggest Q1 2020 reduction was Humana, cutting an estimated $6.07M.
  • Integral Health Asset Management fully exited Agilent Technologies in Q1 2020, selling an estimated $14.5M.
  • Integral Health Asset Management's ten largest holdings make up 40% of its $227M portfolio in Q1 2020.
  • Integral Health Asset Management opened 31 new positions and closed 30 in Q1 2020.
  • Integral Health Asset Management's portfolio value fell 12% quarter-over-quarter to $227M.

Based on Integral Health Asset Management's 13F filing for Q1 2020, filed 15 May 2020.